Skip to main content

Peer Review reports

From: Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial

Original Submission
8 Aug 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
15 Sep 2023 Author responded Author comments - Flavio Mantelli
Resubmission - Version 3
15 Sep 2023 Submitted Manuscript version 3
11 Oct 2023 Reviewed Reviewer Report
24 Oct 2023 Reviewed Reviewer Report
27 Mar 2024 Author responded Author comments - Flavio Mantelli
Resubmission - Version 4
27 Mar 2024 Submitted Manuscript version 4
8 Apr 2024 Reviewed Reviewer Report
24 May 2024 Reviewed Reviewer Report
5 Jun 2024 Author responded Author comments - Flavio Mantelli
Resubmission - Version 5
5 Jun 2024 Submitted Manuscript version 5
11 Jun 2024 Author responded Author comments - Flavio Mantelli
Resubmission - Version 6
11 Jun 2024 Submitted Manuscript version 6
Publishing
8 Jul 2024 Editorially accepted
17 Jul 2024 Article published 10.1186/s12886-024-03564-w

You can find further information about peer review here.

Back to article page